News & Updates

Across the RADIANCE trials, individuals treated with renal denervation remain to have a lower medication burden throughout the 6-month follow-up period even after the reintroduction of blood pressure (BP)-lowering drugs.

A post hoc analysis of the CHANCE-2 randomized controlled trial (RCT) demonstrates that ticagrelor-aspirin combination therapy is associated with a significantly lower risk of new stroke within 90 days vs the clopidogrel-aspirin combination in Chinese CYP2C19 loss‐of‐function allele carriers with minor stroke or transient ischaemic attack (TIA) without intracranial artery stenosis (ICAS).

Induction chemotherapy followed by chemoradiotherapy (CRT) significantly improves progression-free survival (PFS) and overall survival (OS) in patients with locally advanced cervical cancer compared with standard CRT alone, according to the INTERLACE trial presented at ESMO 2023.

Treatment with datopotamab deruxtecan (Dato-DXd), an investigational TROP2*-directed antibody-drug conjugate, significantly improves progression-free survival (PFS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, according to the TROPION-Breast01 trial presented at ESMO 2023.

Research in a multiethnic cohort of older adults in Singapore has shown that hearing impairment (HI) is terrible for the quality of life (QoL).